Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel

Nineteen gene panel provides the most comprehensive hereditary cancer analysis clinically available.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Ethigen is thrilled to be leading the industry with the most comprehensive and rationally-priced BRCA testing solution available, enabling patients and their health care providers make the most informed, personalized decisions possible.

Salt Lake City, UT (PRWEB) June 19, 2013

Ethigen announced today the US launch of their expanded BRCA1 and BRCA2 testing service, providing next-generation sequencing (NGS) and rearrangement analysis of both genes. Analysis is available individually, or as part of an expanded hereditary cancer panel, including full coverage of up to seventeen additional genes with known links to cancer risk: MLH1, MSH2, MSH6, APC, MUTYH (MYH), PTEN, TP53, CDK4, STK11, SMAD4, BMPR1A, CDH1, MET, FH, FLCN, PDGFRA, and KIT.

The expanded panel represents the most advanced and comprehensive hereditary cancer analysis in the market today. Genetics professionals may select BRCA analysis only, or select from any combination of the other seventeen available genes at no additional cost. This unique structure provides clinicians with the ability to tailor the breadth of analysis to the patient’s specific family history and desire for information.

“We’re entering a new era of testing for hereditary cancer risk, with better and more complete tests available at increasingly affordable price points,” said Eric M. Dyer, President of Ethigen, LLC. "Ethigen is thrilled to be leading the industry with the most comprehensive and rationally-priced BRCA testing solution available, enabling patients and their health care providers make the most informed, personalized decisions possible.”

Ethigen provides CLIA-certified NGS testing services for numerous genetic disorders, with a primary focus on the hereditary cancer syndromes including hereditary breast and ovarian cancer (HBOC), Lynch syndrome, and the varied polyposis syndromes. Founded in 2011, the company works exclusively with licensed genetics professionals.

“With these more inclusive tests, the need for specific training in the interpretation and reporting of potentially complex genetic results has never been more important. Ethigen strongly advocates for the involvement of a Certified Genetic Counselor, and requires their participation with every test we offer,” said Dyer. “We look forward to working in partnership with the genetic counseling community to better serve the multitudes of individuals who remain in need of appropriate counseling and testing for these common and highly manageable disorders.”

About Ethigen™

Ethigen is a privately-held, international provider of laboratory testing services, committed to ensuring a more informed and responsible future for genetic testing. Ethigen is driven by three guiding principles: to provide the most advanced, clinically relevant genetic testing solutions possible; to encourage more fair and rational pricing for genetic testing services; and to aggressively advocate for the critical role served by the Certified Genetic Counselor throughout the testing process.

Ethigen’s services are certified by the College of American Pathologists (CAP), Clinical Laboratories Improvement Act (CLIA), and Clinical Pathology Accreditation (CPA), with a primary emphasis on the hereditary cancer disorders affecting millions worldwide.

Ethigen seeks to always maintain an ethical awareness of the small but important role it plays in ensuring that genetic science is always used to advance the best interests of patients, genetics professionals, and the community at large. For more information, visit http://www.ethigen.net.

Media Contact:
Eric M. Dyer, President
edyer(at)ethigen(dot)net
(888) 578-7872
http://www.ethigen.net


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn